Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
It is time to put the record straight about ways of
controlling selection bias when generating comparison groups in clinical trials. D'Arcy Hart has done history a great service by
noting that Bradford Hill's motivation for replacing alternation with
randomisation was "to better conceal the allocation
schedule."1 This is what Guy Scadding (who, with D'Arcy
Hart, is the other surviving member of the team who designed the
streptomycin trial) told Mike Clarke and me when we visited him on 10 June 1999, and what Bradford Hill told William Silverman and me when we
visited him on 3 April 1982.
Bradford Hill's motivation for concentrating on the concealment
of the allocation schedule in the streptomycin trial seems likely to
have been stimulated more than a decade earlier. A Medical Research
Council trial of serum treatment for lobar pneumonia had used an
(unconcealed) allocation schedule based on alternation,2 and important imbalances in the